title: Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study.
abstract: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) ± rituximab [(± R)CHOP] is the current standard of care for aggressive non-Hodgkin lymphoma (NHL). Anemia resulting from chemotherapy can be treated with erythropoiesis-stimulating agents (ESAs). As part of the observational IMPACT NHL study, data were collected on ESA use and anemia-related outcomes in 1829 adults receiving (± R)CHOP-14 or (± R)CHOP-21. Overall, 33% of patients were anemic during chemotherapy. Older age, lower baseline hemoglobin (Hb), worse performance status, more advanced disease stage, and use of CHOP-14 were significant predictors of transfusion and anemia in logistic regression models. ESAs were received by 404 patients, usually in response to low or declining Hb levels. Most patients (65%) had Hb 9-11 g/dL at ESA initiation, and 89% (Kaplan-Meier percentage) achieved Hb 10-12 g/dL. In conclusion, two-thirds of anemic patients with NHL receiving (± R)CHOP initiated ESA treatment at Hb 9-11 g/dL, and most achieved target Hb levels (10-12 g/dL).
authors.affiliation: Hematology Department, Henri Mondor Hospital, Creteil, France. corinne.haioun@hmn.aphp.fr
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
authors.forename: Antonio
authors.initials: A
authors.lastname: Salar
authors.forename: Ruth
authors.initials: R
authors.lastname: Pettengell
authors.forename: Hans Erik
authors.initials: HE
authors.lastname: Johnsen
authors.forename: Ulrich
authors.initials: U
authors.lastname: Duehrsen
authors.forename: Francesca Gaia
authors.initials: FG
authors.lastname: Rossi
authors.forename: Gregor
authors.initials: G
authors.lastname: Verhoef
authors.forename: Matthias
authors.initials: M
authors.lastname: Schwenkglenks
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jaeger
authors.forename: Lisa
authors.initials: L
authors.lastname: Hamilton
authors.forename: Beatriz
authors.initials: B
authors.lastname: Pujol
authors.forename: Pieternella Johanna
authors.initials: PJ
authors.lastname: Lugtenburg
mesh_terms: D000368:Aged; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019370:Observation; D011239:Prednisolone / Q000008:administration & dosage; D012189:Retrospective Studies; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D006397:Hematinics; D006454:Hemoglobins; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone